These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27587627)

  • 1. Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer.
    Hacker KE; Uppal S; Johnston C
    J Natl Compr Canc Netw; 2016 Sep; 14(9):1175-82. PubMed ID: 27587627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiologic features of borderline ovarian tumors in California: a population-based study.
    Morris CR; Liu L; Rodriguez AO; Cress RD; Snipes K
    Cancer Causes Control; 2013 Apr; 24(4):665-74. PubMed ID: 23314731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of zinc finger transcription factors (ZNF143 and ZNF281) in serous borderline ovarian tumors and low-grade ovarian cancers.
    Sadłecki P; Grabiec M; Grzanka D; Jóźwicki J; Antosik P; Walentowicz-Sadłecka M
    J Ovarian Res; 2019 Mar; 12(1):23. PubMed ID: 30885238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies in borderline ovarian tumors.
    Seong SJ; Kim DH; Kim MK; Song T
    J Gynecol Oncol; 2015 Oct; 26(4):343-9. PubMed ID: 26404125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of Platelet-derived Growth factor receptors (PDGFRs) and their correlation with overall survival of patients with ovarian cancer.
    Szubert S; Moszynski R; Szpurek D; Romaniuk B; Sajdak S; Nowicki M; Michalak S
    Ginekol Pol; 2019; 90(5):242-249. PubMed ID: 30977516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): single institution experience.
    Chen RF; Li J; Zhu TT; Yu HL; Lu X
    J Ovarian Res; 2016 Mar; 9():16. PubMed ID: 26988551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utero-ovarian preservation and overall survival of young women with early-stage borderline ovarian tumors.
    Mandelbaum RS; Blake EA; Machida H; Grubbs BH; Roman LD; Matsuo K
    Arch Gynecol Obstet; 2019 Jun; 299(6):1651-1658. PubMed ID: 30923905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns.
    Eichhorn JH; Bell DA; Young RH; Scully RE
    Am J Surg Pathol; 1999 Apr; 23(4):397-409. PubMed ID: 10199469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
    Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
    Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants.
    Leary A; Petrella MC; Pautier P; Duvillard P; Uzan C; Tazi Y; Ledoux F; Gouy S; Morice P; Lhommé C
    Gynecol Oncol; 2014 Jan; 132(1):23-7. PubMed ID: 24219980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective evaluation of borderline ovarian tumors: single center experience of 183 cases.
    Gungor T; Cetinkaya N; Yalcin H; Ozdal B; Ozgu E; Baser E; Uygur D; Caglar M; Sirvan L; Erkaya S
    Arch Gynecol Obstet; 2015 Jan; 291(1):123-30. PubMed ID: 25047273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].
    Rousset-Jablonski C; Selle F; Adda-Herzog E; Planchamp F; Selleret L; Pomel C; Chabbert-Buffet N; Daraï E; Pautier P; Trémollières F; Guyon F; Rouzier R; Laurence V; Chopin N; Faure-Conter C; Bentivegna E; Vacher-Lavenu MC; Lhomme C; Floquet A; Treilleux I; Lecuru F; Gouy S; Kalbacher E; Genestie C; de la Motte Rouge T; Ferron G; Devouassoux-Shisheboran M; Kurtz JE; Namer M; Joly F; Pujade-Lauraine E; Grynberg M; Querleu D; Morice P; Gompel A; Ray-Coquard I
    Bull Cancer; 2018 Mar; 105(3):299-314. PubMed ID: 29397916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Borderline ovarian tumors: clinical characteristics, management, and outcomes - a multicenter study.
    Gokcu M; Gungorduk K; Aşıcıoğlu O; Çetinkaya N; Güngör T; Pakay G; Cüylan ZF; Toptaş T; Özyurt R; Ağaçayak E; Ozdemir A; Erol O; Turan A; Gülseren V; İcen MS; Şenol T; Güraslan H; Yücesoy B; Sahbaz A; Gungorduk O; Besimoğlu B; Pakay K; Temizkan O; Sancı M; Şimşek T; Meydanlı MM; Harma M; Yaşar L; Boran B; Uysal AD; Karateke A
    J Ovarian Res; 2016 Oct; 9(1):66. PubMed ID: 27756415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Borderline ovarian tumors: current concepts for prognostic factors and clinical management.
    Jones MB
    Clin Obstet Gynecol; 2006 Sep; 49(3):517-25. PubMed ID: 16885658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.